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Introduction
Blood-borne metastasis is initiated by cancer cells that are trans-
ported through the circulation from the primary tumor to vital dis-
tant organs, and it is directly responsible for most cancer-related 
deaths. Addressing this challenge, however, is confounded by our 
limited understanding of the process by which tumor cells exit 
from their primary site, intravasate into the circulation, and then 
establish distant lesions in the lung, brain, liver, or bone. Tumor 
cells that are identified in transit within the blood stream are re-
ferred to as circulating tumor cells (CTCs). Although their exact 
composition is unknown, a fraction of these are thought to be via-
ble metastatic precursors capable of initiating a clonal metastatic 
lesion. However, CTCs are extraordinarily rare (estimated at one 
CTC per billion normal blood cells in the circulation of patients 
with  advanced  cancer);  our  understanding  of  their  biological 
properties has thus been limited by the availability of technologies 
capable of isolating them in sufficient numbers and under condi-
tions that are compatible with detailed molecular and functional 
experiments.  Despite  the  limitations  of  current  CTC-isolating 
methods, circulating cancer cells have been detected in a majority 
of epithelial cancers, including those from breast, prostate, lung, 
and colon. Patients with metastatic lesions are more likely to have 
CTCs detected in their blood; however, these have also been re-
ported in some localized cancers. A better understanding of the 
identity of CTCs and the factors underlying their shedding into 
the vasculature is critical to identifying the key drivers of human 
cancer metastasis and devising rational therapeutic approaches.
Much of our current understanding of processes involved 
in cancer metastasis has been derived from mouse models of me-
tastasis. Recent studies in these models have raised interesting 
mechanistic insights. For example, CTCs captured in xenograft 
prostate cancer models have highlighted the importance of   
pathways  conferring  resistance  to  apoptosis  in  these  cells   
(Berezovskaya et al., 2005; Howard et al., 2008; Helzer et al., 
2009). In a mouse model of breast cancer, disseminated tumor cells 
(DTCs) in the bone marrow can be detected in the premalignant 
phases of breast cancer, suggesting an early spread to distant or-
gans (Hüsemann et al., 2008). Studies of the effects of epithelial–
mesenchymal transition (EMT) in the generation of CTCs and 
distal metastases have suggested that this mesenchymal trans-
formation may enhance the ability of cells to intravasate but may 
reduce their competence to initiate overt metastases (Tsuji et al., 
2008, 2009). Mouse studies have also identified bone marrow–
derived hematopoietic progenitor cells that express VEGF recep-
tor 1 (VEGFR1) and may form a premetastatic niche that precedes 
the arrival of tumor cells (Kaplan et al., 2005). Moreover, Kim   
et al., (2009) have recently proposed a new concept of tumor self-
seeding, in which injected tagged human cancer cell lines may 
colonize an existing tumor deposit, with the newly recruited   
tumor cells conferring increased aggressiveness to the existing 
tumor. Finally, the possibility of intravascular proliferation of 
CTCs adherent to vascular endothelium has been proposed based 
on in vivo imaging of tagged cells (Al-Mehdi et al., 2000).
Although these mouse studies offer fascinating insights into 
potential mechanisms of metastasis, certain limitations apply: xeno-
graft models using established human cancer cell lines do not   
recapitulate the complex evolving vasculature and microenviron-
ment of endogenous cancers, nor, of course, does direct intravascu-
lar inoculation of cancer cell lines into the tail vein. On the other 
hand, most endogenous mouse tumor models metastasize late, if at 
Circulating  tumor  cells  (CTCs)  shed  from  primary  and 
metastatic cancers are admixed with blood components 
and are thus rare, making their isolation and character-
ization a major technological challenge. CTCs hold the 
key to understanding the biology of metastasis and pro-
vide a biomarker to noninvasively measure the evolution 
of tumor genotypes during treatment and disease pro-
gression. Improvements in technologies to yield purer CTC 
populations  amenable  to  better  cellular  and  molecular 
characterization  will  enable  a  broad  range  of  clinical   
applications, including early detection of disease and the 
discovery of biomarkers to predict treatment responses 
and disease progression.
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Yoon et al., 2009), whereas others have first purified nucleated cells 
followed by lysis and nucleic acid extraction. Molecular analysis 
of DNA mutations have been described previously (Igetei et al., 
2008), and individual tumor-specific translocation breakpoints 
have recently been sequenced by next-generation approaches 
(Leary et al., 2010). Overall, the relatively low sensitivity of nucleic 
acid analyses from free plasma or unpurified blood cell compo-
nents has been addressed by sampling relatively large blood vol-
umes as well as application of such next-generation sequencing 
technologies with extraordinary sensitivity. Nonetheless, inter-
pretation of a negative test remains a concern because absence of a 
defined molecular abnormality within a blood specimen cannot be 
readily distinguished from insufficient amounts of tumor-derived 
DNA in the circulation from an individual patient. At the RNA 
level, RT-PCR analyses have also been applied, either to unpurified 
plasma nucleic acids (Papadopoulou et al., 2006) or more com-
monly to enriched CTC populations. Tumor cell–specific mark-
ers have included cytokeratins, prostate-specific antigen (PSA),   
mucin-1 (MUC-1), HER2, AFP (-fetoprotein), and the CEA 
(carcinoembryonic antigen) gene family among others (Louha 
et al., 1997; de Cremoux et al., 2000; Hardingham et al., 2000; 
Mejean et al., 2000; Wu et al., 2006; Xi et al., 2007). However, 
significant challenges include the frequency of both false-
positive and false-negative PCR results and the difficulty in quan-
titating relative levels of expression without prepurification of 
these extraordinarily rare cells (Paterlini-Brechot and Benali, 
2007; Pantel et al., 2008).
Detection  of  CTCs  based  on  their  physical 
properties. Although not absolute, several physical properties 
distinguish CTCs from most normal blood cells. These include 
the larger size of most epithelial cells and differences in density, 
charge, migratory properties, and some properties of specific cell 
types (e.g., melanocytic granules in melanoma cells). Differences 
in buoyant density have been used to separate mononucleated 
cells, including CTCs, from red blood cells through gradient 
centrifugation, although CTCs still comprise a minute fraction   
of mononucleated cells in the circulation (Gertler et al., 2003; 
Müller et al., 2005; Wülfing et al., 2006; Morgan et al., 2007).
Isolation of CTCs by virtue of their increased size, com-
pared with leukocytes, has been applied using several different 
filtration-based approaches, such as isolation by size of epithe-
lial tumor cells (Vona et al., 2000) and microelectromechanical 
systems (Zheng et al., 2007). Although most CTCs derived from 
epithelial cancers are in fact larger than leukocytes, there is a 
significant variation in their size range (Marrinucci et al., 2007). 
Several different pores and filter-based approaches have been 
developed to prevent clogging and facilitate the retrieval of CTCs 
(Mohamed et al., 2009; Tan et al., 2009). These approaches have 
shown significant promise in capturing cancer cell lines spiked 
into blood but will require further validation with clinical speci-
mens, in which both heterogeneous CTC size and resistance to 
filtering shear stress are likely to be significant variables.
Capture of CTCs using antibodies against cell 
surface  antigens.  The  most  widely  used  CTC  isolation 
techniques rely on antibody-based capture of CTCs, which ex-
press epithelial cell surface markers that are absent from normal 
leukocytes. Among these, epithelial cell adhesion molecule 
all, often in the setting of a massive primary tumor. Thus, although 
instructive, mechanistic insights from experimental mouse models 
must be validated by observational studies in human cancer.
The  emergence  of  increasingly  advanced  and  sensitive 
technologies to isolate human CTCs provides the opportunity to 
extend studies of cancer metastasis directly to human cancer. The 
full range of potential applications for CTC analyses include real-
time noninvasive monitoring of CTCs as biomarkers of either 
sensitivity or acquired resistance to new cancer therapies, identi-
fying new potential therapeutic targets to directly suppress cancer 
metastasis, and as technologies for CTC detection become in-
creasingly sensitive and reliable, applying these at earlier stages 
of cancer progression with the goal of early cancer detection.
Although the potential applications of CTC analyses appear 
extraordinarily promising, the development of appropriate, high 
throughput, and reliable technological platforms for rare tumor cell 
detection within blood specimens remains the critical impediment. 
In  fact,  appropriate  interpretation  of  many  reported  molecular 
analyses of CTCs requires an understanding of the technical limi-
tations of the assays used to make these observations. In the fol-
lowing sections, we will review the technologies currently available 
for CTC isolation and the utility of CTCs as a diagnostic and prog-
nostic marker in various cancers and focus on the molecular prop-
erties of these rare cells, which may help define their biology.
CTC detection technologies
The presence of CTCs in an autopsy of a patient who succumbed 
to  advanced  metastatic  cancer  was  first  reported  in  1869   
(Ashworth, 1869). To date, however, only limited information is 
available about the numbers of these cells in the blood stream at 
different stages of cancer and in different types of cancer, their 
molecular and biological heterogeneity, and their significance in 
the natural history of the disease. In the absence of any gold stan-
dard with which to measure various technologies, defining their 
absolute accuracy, sensitivity, and specificity in detecting CTCs 
remains a challenge. The ultimate goal, i.e., to efficiently isolate 
this rare population of cells in a viable and intact state and with 
high purity from the vast number of surrounding blood cells, 
presents a formidable technological challenge. A variety of cur-
rently used approaches relying on either the physical properties, 
expression of biomarkers, or functional characteristics of CTCs 
are reviewed in the following sections. Although none of these 
current approaches constitute the optimal platform for CTC isola-
tion, they each represent significant advances and provide a basis 
from which to anticipate ongoing technological developments.
Nucleic acid–based detection of CTCs. Free DNA 
and, to a lesser extent, RNA circulating in plasma from patients 
with cancer have been described previously (Papadopoulou et al., 
2006; Gormally et al., 2007; Zanetti-Dällenbach et al., 2008; Yoon 
et al., 2009). Schwarzenbach et al. (2007, 2009) have suggested a 
link between the presence of CTCs (and DTCs) and the detection 
of free tumor-derived DNA in serum/plasma of prostate cancer pa-
tients. However, the origin of these nucleic acids may also include 
direct shedding from necrotic cells in tumor deposits, tumor- 
derived exosomes, or cellular fragments or lysis of CTCs in the 
bloodstream. Some approaches have focused on isolating nucleic 
acids directly from cell-free plasma (Papadopoulou et al., 2006; 375 Visualizing and analyzing circulating tumor cells • Yu et al.
(Nagrath et al., 2007; Maheswaran et al., 2008; Stott et al., 2010a). 
The CTC-chip is a silicon chamber etched with 78,000 micro-
posts that are coated with an anti-EpCAM antibody. As 2–4 ml of 
whole blood flows through the chip, flow kinetics have been opti-
mized for minimal shear stress on cells while enhancing contacts 
with the antibody-coated microposts. Captured CTCs attached to 
microposts are visualized by staining with antibodies against cyto-
keratin or tissue-specific markers (Fig. 1). For CTC enumeration, 
the entire device is imaged at multiple planes using a semiauto-
mated imaging system while on-chip lysis allows for DNA and 
RNA extraction and molecular analyses (Fig. 2). The CTC-chip 
enables a high yield of capture (median, 50 CTCs per milliliter) 
and purity (ranging from 0.1 to 50%), most likely caused by the 
gentle one-step microfluidic processing, which may be critical 
when  purifying  rare  delicate  cell  populations  (Nagrath  et  al., 
2007). Captured cells remain viable after capture, although the 
absence of cell fixation currently limits the time allowed between 
blood collection and microfluidic analysis to a few hours. Al-
though the CTC-chip assay is technically difficult and not yet 
standardized for high throughput applications, the high number of 
cells captured provides a dynamic range that allows longitudinal 
monitoring of patients during therapy while improved (albeit still 
highly variable) purity of captured CTCs enables molecular char-
acterization (see Molecular characterization of CTCs). Recently, 
we have improved the microfluidic CTC isolation approach using 
an enhanced platform, the herringbone (HB)-chip, which makes 
use of a microvortex mixing device (Stott et al., 2010b). Instead of 
(CAM [EpCAM]) is most commonly used because its expression 
is virtually universal (albeit at variable levels) in cells of epithelial 
origin, but it is absent in blood cells. Conjugation of antibodies 
against EpCAM to magnetic beads, followed by purification of 
captured cells through a magnetic field, has been used to enrich 
CTCs from the blood of patients with cancers of the breast, pros-
tate, and colon. The CellSearch system (Veridex), a widely used 
FDA (Food and Drug Administration)–approved method, uses 
ferrofluids loaded with an EpCAM antibody to capture CTCs, 
which are subsequently visualized by staining with a cocktail of 
antibodies against the cytoplasmic epithelial cytokeratins (8, 18, 
and 19; Riethdorf et al., 2007). Staining for the leukocyte-specific 
marker CD45 is used as a control to exclude contaminating   
leukocytes. Surprisingly, a significant number of cells appears to 
stain both for cytokeratins and CD45; although the identity of 
these dual-positive cells is not well understood, they are excluded 
from enumeration, with CTCs defined as the subset of EpCAM-
captured cells that are confirmed as both positive for cytokeratins 
and negative for CD45. Although this platform is the most stan-
dardized of any current technology and is now being tested for 
clinical applications (see CTCs as prognostic markers), it suffers 
from relatively low sensitivity: only a fraction of patients with 
metastatic cancer scores positive for any CTCs, with a median 
yield of approximately one CTC per milliliter and typically low 
purity (Allard et al., 2004; Attard et al., 2009).
Our own group has developed a microfluidic platform for 
single-step isolation of CTCs from unprocessed blood specimens 
Figure 1.  Micrographs of CTCs captured from 
patients’ blood using an anti-EpCAM–coated 
CTC-chip. (A–C) Combined fluorescent and re-
flected light micrographs of a cytokeratin 7/8 
(green)–stained  CTC  captured  from  breast 
cancer  patient  blood  and  a  contaminating 
CD45-positive (red) white blood cell (A) and 
cytokeratin  7/8  (green,  B)–  and  PSA  (green, 
C)-stained  CTCs  captured  from  a  prostate   
cancer  patient.  (D  and  E)  HER2  (green,  D)- 
and cytokeratin 7/8 (green, E)–stained CTCs   
captured  from  a  breast  cancer  patient.   
(F  and  G)  Individual  and  merged  fluorescent 
micrographs of CTCs captured from prostate 
cancer patients’ blood stained positive for PSA 
(green) and Ki-67 (red, proliferative marker, F),   
and  PSA  (green)  and  M30  (red,  apoptotic 
marker)  demonstrated  the  heterogeneity  in   
CTCs  (G). In all panels, the nuclei are stained   
with  DAPI  (blue).  CK7/8,  cytokeratin  7/8. 
Bars, 10 µm.JCB • VOLUME 192 • NUMBER 3 • 2011   376
by using a combination of fluorescent labeling and forward 
scatter to enhance identification of cells deposited on a glass 
slide (Pachmann et al., 2005b). Both fiber-optic array–scanning   
technology and laser-scanning cytometry enable cytological evalu-
ation of CTCs without the preselection bias derived from reliance 
on their expression of specific cell surface markers, but the identifi-
cation of unpurified viable CTCs is less conducive for further mo-
lecular and biological characterization. Multiphoton intravital flow 
cytometry detects CTCs tagged in vivo using injected fluores-
cent ligands as they flow through the vasculature (He et al., 2007). 
Dielectric properties of cells, a measure of their plasma membrane 
area affected by ruffles, folds, and microvilli, have also been used 
to isolate CTCs from mixed cell populations (Gascoyne et al., 
2009). Photoacoustic flowmetry, making use of the broadband ab-
sorption spectrum of melanin, has been tested to detect melanoma 
cells (Weight et al., 2009) and has been combined with nanoparti-
cles targeting cell surface antigens to broaden its applicability in 
CTC detection (Galanzha et al., 2009a, b). The proclivity of meta-
static cells to ingest and invade through collagen has led to the de-
velopment of a technique whereby mononucleated blood cells are 
seeded on fluorescent CAM-coated slides, and CTCs are visual-
ized as they ingest CAM (Paris et al., 2009; Lu et al., 2010).   
Finally, staining of CTCs by virtue of detectable secreted products 
(epithelial immunospot) has been developed as a functional screen 
(Alix-Panabières et al., 2007, 2009). Of note, most new technolo-
gies are developed and tested using cancer cell lines spiked into 
control blood specimens. Extrapolation to the detection of real 
CTCs in blood specimens from cancer patients presents a signifi-
cant challenge beyond cancer cell line experiments, given their 
heterogeneity, variable expression of cell surface markers, and re-
duced ability to survive intact through complex purification pro-
cedures. Hence, extensive validation of novel technologies using 
clinical specimens should be an integral part of assay development.
In summary, the existing CTC technologies rely on vari-
ous properties of CTCs, with each having unique advantages 
using three-dimensional microposts to break up flow streamlines 
and enhance cell collisions with antibody-coated posts, the   
HB-chip uses calibrated microfluidic flow patterns to drive cells 
into contact with the antibody-coated walls of the device. In addi-
tion to increased target cell capture efficiency, the less complex 
design of the HB-chip is more amenable to high throughput man-
ufacture and reliable coating of the inner surface with antibodies 
and allows for the chambers to be made out of transparent materi-
als, which greatly enhance high resolution imaging, including the 
use of transmitted light microscopy.
Additional  cell  surface  marker–based  CTC  detection 
platforms are under development. Among these, standard flow   
cytometry (FACS) has been tested (Simpson et al., 1995; Cruz 
et al., 2005), although its sensitivity may be inadequate for de-
tection of extraordinarily rare cells (Allan et al., 2005). A mag-
netic stir bar, the slowly rotating MagSweeper, coated with an 
antibody to EpCAM has also been tested to capture CTCs from 
blood samples (Talasaz et al., 2009). To avoid the bias of select-
ing cells by virtue of EpCAM expression, negative selection 
(i.e., removal of leukocytes, thereby leaving residual CTCs) has 
been advocated. Although this strategy has the potential to 
purify CTCs irrespective of presumed cell surface markers, the 
extremely low prevalence of CTCs limits the yield accomplished 
by negative selection (Tong et al., 2007; Tkaczuk et al., 2008; 
Balasubramanian et al., 2009; Yang et al., 2009).
Additional innovative CTC detection strategies. 
Several additional innovative approaches have been developed 
with the goal of detecting these rare cells. Some of these make use 
of interesting physical or biological properties of epithelial cells. 
High throughput microscopic scanning approaches have been 
adapted to screen for CTCs. Among these, fiber-optic array– 
scanning technology involves deposition of nucleated cells on the 
surface of a large glass slide, with scanning of cells positive for epi-
thelial or tumor-specific antigens (Krivacic et al., 2004; Marrinucci 
et al., 2007). Laser-scanning cytometry extends this approach 
Figure 2.  Illustration of current and potential 
applications of CTC technologies. The periph-
eral  blood  of  a  cancer  patient  is  collected 
and processed through various CTC isolation 
technologies. CTCs are captured along with 
contaminating leukocytes. Immunostaining for 
specific markers and FISH for genomic ampli-
fication and translocation can be applied to 
CTCs. DNA or RNA can be extracted from the 
CTCs and subjected to sequencing, quantita-
tive RT-PCR (qRT-PCR), and potential expression 
profile analysis. Viable cells can be released 
and propagated in cell culture.377 Visualizing and analyzing circulating tumor cells • Yu et al.
CTC analyses in monitoring responses  
to therapy
Whereas prognostic studies have focused on clinical outcomes 
for patients who have baseline CTC counts above or below an   
arbitrary threshold, correlating CTC numbers over time with re-
sponse to therapy requires that the CTC detection method be 
sensitive enough to provide a dynamic range that can be followed 
over time. Using a microfluidic CTC capture device, we were 
able to show that the number of CTCs in patients with lung, pros-
tate, and other cancers declined rapidly after the initiation of   
effective  chemotherapy,  hormonal  therapy,  or  targeted  kinase   
inhibition (Nagrath et al., 2007; Maheswaran et al., 2008; Stott   
et al., 2010a). Again, there was little correlation among different 
patients between baseline CTC counts and radiographical mea-
sures of tumor volume before therapy. However, treatment-induced 
changes  in  CTC  numbers  within  individual  patients  followed   
longitudinally were well correlated with standard measures of   
tumor response, irrespective of baseline levels. Treatment-induced 
changes in CTC numbers have also been reported in some early 
breast cancer treated with neoadjuvant therapy using laser- 
scanning cytometry (Pachmann et al., 2005a) and CellSearch 
(Pierga et al., 2008), in adjuvant chemotherapy using OncoQuick 
(Müller et al., 2005), and in some metastatic breast and prostate 
cancers using immunomagnetic bead isolation (Hayes et al., 2006; 
Attard et al., 2009; Reid et al., 2010). Additional studies will be 
needed to determine whether monitoring the decline in CTC num-
bers after therapy is useful as an early marker of response or as a 
distinct predictor of overall therapeutic benefit. Eventually, CTC-
based molecular analyses may have the added benefit of demon-
strating direct inhibition of drug targets in viable tumor cells.
Although testing for chemotherapy-induced changes in 
CTC numbers may provide insight into treatment effectiveness 
for advanced cancers, monitoring the number of CTCs after cu-
rative surgical resection of localized cancers may identify cases 
that are at risk for disease recurrence. Measurements of CTCs in 
patients with localized cancer have been limited and require 
sensitive assays. In a pilot study of 19 patients with localized 
prostate cancer, we detected CTCs in eight cases (Stott et al., 
2010a). In most of these, CTCs dropped to undetectable levels 
within 24 h of surgical resection, whereas in a few cases, a more 
delayed decline after surgery was evident. None of these pa-
tients have developed a recurrence at a 1-yr follow up. Although 
these studies are preliminary, they raise the possibility that local-
ized cancers may invade the vasculature and shed CTCs before 
metastases are established, a concept that provides hope for 
early cancer detection applications. The prognostic significance 
of CTCs shed by localized cancers and the rate of decline of 
CTCs after surgical resection remain to be determined.
Molecular characterization of CTCs
Identification  of  molecular  aberrations  in  CTCs. 
Beyond the enumeration of CTCs, their molecular characteriza-
tion provides a key to demonstrating their cellular origin from 
primary and metastatic tumor deposits, and it may also provide 
clues to their evolution during the course of cancer treatment.
FISH analysis performed on CTCs from breast, kidney, 
prostate, and colon cancer showed evidence of aneuploidy in 
and limitations. Additional technologies are under development, 
and future CTC capture platforms should aim for an efficient 
capture of the entire diverse spectrum of tumor cells that circu-
late in the blood, followed by their molecular and functional 
characterization. The inherent limitations of current CTC detec-
tion platforms should be considered when interpreting the liter-
ature about molecular properties of CTCs and their potential 
clinical applications.
CTCs as prognostic markers
Despite the limitation of the various CTC detection technologies, 
several studies with large cohorts of patients have been performed 
to evaluate the clinical utility of CTC enumeration. Given the 
need for high throughput standardization, most of these studies 
have used the immunomagnetic bead capture assay, which is 
commercially available. In general, these studies have concluded 
that the presence of detectable CTCs in the blood serves as an in-
dependent prognostic factor in patients with cancers of the breast, 
prostate, and colon. In patients with metastatic breast cancer, 
CTC counts above five CTCs per 7.5 ml of blood before the 
start of systemic therapy were associated with a shorter median 
progression-free survival and overall survival (Cristofanilli et al., 
2004, 2008; Botteri et al., 2010). Additional studies extended 
these analyses to use molecular endpoints, such as HER2 stain-
ing, and to patients with invasive localized breast cancer receiving 
so-called neoadjuvant chemotherapy (Wülfing et al., 2006; Pierga 
et al., 2008). However, despite processing as much as 50 ml of 
blood, CTCs were detected in only half of the patients, with the 
number of HER2-positive cells ranging from one to eight CTCs 
per 50 ml. Thus, although promising, these approaches empha-
size the critical need for increased sensitivity in CTC detection to 
enable clinical applications. As with breast cancer, a correlation 
between pretreatment CTC numbers and clinical prognosis has 
been reported for patients with colorectal (Cohen et al., 2006)   
and prostate cancers (Danila et al., 2007; de Bono et al., 2008; 
Okegawa et al., 2009). Although these major prognostic studies 
have focused on CTC enumeration using immunomagnetic bead 
capture, others have correlated patient outcomes with the RT-PCR 
analysis of unpurified mononucleated blood cell fractions to test 
for expression of epithelial markers, including various keratins 
and EpCAM (Weigelt et al., 2003; Masuda et al., 2005; Ignatiadis 
et al., 2007). Quantifying PCR-based analysis of epithelial marker 
expression without purification of rare CTCs from the massive 
number of normal leukocytes in the circulation presents a signifi-
cant technical hurdle, although next-generation sequencing tech-
nologies may help address this challenge in the future.
Whichever technique for measuring CTCs is used, most 
have shown that baseline (i.e., pretreatment) CTC numbers 
among  different  cancer  patients  are  not  well  correlated  with 
standard measures of tumor mass, including tumor size deter-
mined radiographically by x ray or CT (computed tomography) 
scan or serum protein markers, such as PSA levels in prostate 
cancer (Budd et al., 2006; Scher et al., 2009; Stott et al., 2010a). 
Thus, the number of CTCs in the blood is not simply a measure 
of tumor volume, but instead, it may reflect additional biological 
features, possibly including tumor vascularity or invasiveness, 
both of which may have distinct prognostic contributions.JCB • VOLUME 192 • NUMBER 3 • 2011   378
Evaluation  of  signaling,  proliferation,  and 
apoptosis in CTCs. Dynamic studies of CTCs after thera-
peutic interventions may eventually allow real-time monitoring 
of treatment responses, a major goal of drug development.   
The signaling markers studied include phospho-PI3K and   
phospho-Akt in breast cancer CTCs (Kallergi et al., 2008) and the 
DNA damage marker phosphorylated -H2AX in patients treated 
with chemotherapeutic agents (Wang et al., 2010). Evidence of 
apoptosis in CTCs has also been tested using morphological crite-
ria as well as flow cytometric analysis of M30-stained cells (Larson   
et al., 2004; Hou et al., 2009; Swennenhuis et al., 2009). Up- 
regulation of the antiapoptotic BCL2- transcript in CTCs cap-
tured from mice harboring PC3 xenografts has also been reported 
(Helzer et al., 2009). Collectively, monitoring intracellular signal-
ing pathways is likely to significantly enhance the utility of CTC 
analyses, although early studies have been limited both by the 
challenge of low amounts of RNA or protein recovery from these 
rare cells and by the need for dynamic analysis over time using a 
sufficient number of CTCs within each clinical specimen.
Although the use of apoptotic markers may be compli-
cated by the effect of ex vivo processing, analysis of cellular 
proliferation markers appears to be particularly promising using 
the microfluidic chip. In early studies, costaining of prostate 
cancer CTCs for the tumor-specific marker PSA together with 
the proliferation marker Ki-67 revealed significant variation in 
the proliferative index of CTCs (Stott et al., 2010a). In a pilot 
study of metastatic prostate cancer, CTCs from patients who 
were responding to hormone withdrawal therapy exhibited a 
low proliferative index (1–2%), whereas a much higher Ki-67–
positive fraction was scored in CTCs from treatment-resistant 
patients (69–73%; Stott et al., 2010a). These results need to be 
verified using a larger cohort of patients but suggest that a sig-
nificant heterogeneity in the proliferative index of CTCs may 
reflect the intrinsic biological properties of tumors, with poten-
tial applications in assessing therapeutic responses.
Molecular characterization of CTCs may also provide in-
sight into the biology of these cells and their link to the process of 
metastasis. Mouse models and in vitro experiments have suggested 
that EMT, together with stemlike properties in cancer cells, is as-
sociated with increased cellular migration and resistance to therapy 
(Mani et al., 2008; Polyak and Weinberg, 2009). Although defini-
tive studies of EMT and stem cell markers in CTCs are lacking, 
some studies of tumor cells isolated from bone marrow biopsies 
(so-called DTCs) have suggested the expression of characteristic 
EMT markers, either in the cells themselves or in derivative cell 
lines (Putz et al., 1999; Schardt et al., 2005; Willipinski-Stapelfeldt 
et al., 2005). PCR assays have suggested a possible expression of 
some EMT inducers in CTC-enriched blood specimens (Aktas   
et al., 2009). However, an intrinsic challenge in studying EMT in 
CTCs is the standard use of an antibody to EpCAM to capture 
these cells, thus preselecting for cells that have retained significant 
expression of epithelial markers. A recent study using the Cell-
Search system has shown that a basal-like breast cancer cell line 
with features of EMT expresses EpCAM levels that are too low to 
allow capture using such antibodies (Sieuwerts et al., 2009).   
Development of alternative CTC isolation strategies, as well as re-
fining the imaging parameters for EMT and other cell fate markers, 
some cells, which was consistent with their malignant origin 
(Fehm et al., 2002). However, these studies were somewhat lim-
ited by the low level of chromosome number variation combined 
with technical limitations in analysis of CTC and contaminating 
leukocytes. In more recent studies, demonstration of specific 
androgen receptor gene amplification, a known biomarker of   
castrate-resistant prostate cancer, has provided clear evidence that   
at least a subset of CTCs are tumor derived (Attard et al., 2009; 
Scher et al., 2009). Intragenic mutations in cancer genes have 
extended these findings, although given the presence of contami-
nating leukocytes in CTC populations, these analyses typically 
require allele-specific PCR assays. In nonsmokers’ lung cancer, 
EGF receptor (EGFR) mutations are particularly relevant be-
cause they are predictive of a dramatic clinical response to EGFR 
kinase inhibitors (Lynch et al., 2004; Paez et al., 2004; Pao et al., 
2004). In our initial studies, EGFR mutations identified in lung 
CTCs were concordant with the mutations known to be present 
in the primary tumor in 12/13 cases (Maheswaran et al., 2008). 
Of note, during longitudinal follow up of these cases, continued 
therapy was associated with the emergence of a kinase inhibitor 
resistance-associated EGFR mutation, which was detectable at 
increasing allelic ratios in CTCs, coincident with the develop-
ment of clinical drug resistance. In addition, CTC analyses after 
prolonged therapy showed the acquisition of additional EGFR 
mutations that were below detection in the primary tumor bi-
opsy, which was suggestive of evolution in the dominant tumor 
clones as a result of treatment-induced selection (Maheswaran   
et al., 2008). Thus, serial analysis of tumor-derived samples may 
allow real-time monitoring of molecular evolution among tumor 
cells, which may be particularly relevant after the use of effec-
tive targeted cancer therapy that applies selective pressures to-
ward the development of drug resistance mechanisms.
The use of CTCs to test for molecular evolution of tumors 
during the course of treatment has also been applied in breast can-
cer, in which some HER2-positive CTCs have been reported in 
breast cancer patients whose primary tumor was HER2 negative 
(Meng et al., 2004; Wülfing et al., 2006; Tewes et al., 2009) as well 
as some HER2-negative CTCs emerging in HER2-positive breast 
cancers subjected to anti-HER2 therapy (Hayes et al., 2002). The 
true frequency of such genotype conversion events remains to be 
established in larger studies. In prostate cancer, the TMPRSS2-
ERG translocation has been detected in CTCs either by FISH or by 
translocation-specific RT-PCR analysis (Attard et al., 2009; Stott   
et al., 2010a). Improving CTC isolation technologies has allowed 
selective RNA-based expression analyses (Ghossein et al., 1995; 
Helzer et al., 2009), but CTC impurity remains a major hurdle for 
all detailed molecular analyses of CTC genomic and transcrip-
tional profiles. For instance, FISH analyses of CTCs can be chal-
lenging when scoring four individual CTCs surrounded by 1,000 
leukocytes with a 4% false-positive rate (Attard et al., 2009). The 
use of fine needle microselection of individual CTCs has provided 
the level of purity required for loss of heterozygosity studies in 
some cases of prostate cancer (Schmidt et al., 2006). However, 
collectively, comprehensive molecular analyses of CTCs will re-
quire enhanced isolation methods that result in a higher degree of 
captured cell purity as well as the use of technologies optimized for 
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CTC clusters, ranging from 3 to 14 cells, in several prostate and 
lung cancer patients (Fig. 3; Stott et al., 2010b). These were readily 
identified using the microfluidic HB-chip, which appears to pre-
serve multicellular aggregates, whereas they were never found with 
our micropost CTC-chip, in which tight distances between the 
microposts presumably prevent the passage of large cellular clus-
ters. Interestingly, when stained with hematoxylin and eosin, most 
CTC clusters have an increased staining intensity relative to indi-
vidual CTCs, suggesting less autolysis in the CTC clusters. This 
raises the intriguing possibility that cells within microclusters might 
be relatively protected either from anoikis associated with loss of 
basement membrane attachment (Zhang et al., 2004, 2008) or per-
haps from the harsh environment and shear stresses of the vascular 
circulation. Collectively, the clinical relevance of CTC clusters ver-
sus single CTCs within the circulation and their potential implica-
tions for metastatic spread warrant further investigation.
Future perspectives
The molecular characterization of CTCs has the potential to 
revolutionize our understanding of cancer metastasis. However, 
technological platforms need significant optimization to enable 
highly sensitive and reliable CTC isolation before the full array 
of currently available molecular tools may be applied. Such 
technologies are likely to emerge in the near future as the broad 
field of microfluidic bioengineering and other new approaches 
are applied to the challenge of rare tumor cell detection in blood 
specimens. Although increasingly sophisticated analytic ap-
proaches will be required to tackle the characteristics of CTCs, 
we can already discern a broad range of potential applications, 
from the noninvasive monitoring of tumor genotypes to the 
will be essential. Finally, the successful isolation of viable CTCs 
capable of extended proliferation in vitro will enable detailed mo-
lecular and functional studies, providing important insight into the 
process of metastasis in human cancers.
CTC clusters. A recent and surprising insight derived 
from CTC analyses has been the finding of clusters of CTCs 
within the circulation of patients with known cancer (Stott et al., 
2010b). Predominant models of cancer metastasis have focused 
on the presumed role of individual cells with increased mobility 
through EMT, migrating into the vasculature and exiting at dis-
tant sites to initiate a metastatic tumor deposit. The finding of 
aggregated tumor cells in the vasculature raises the possibility 
that such tumor emboli may also contribute to the metastatic 
process. Work in animal models has shown that intravenously 
injected tumor cell clumps have a greater tendency to form me-
tastases than comparable numbers of single tumor cells (Watanabe, 
1954; Fidler, 1973). Increased metastatic potential has also been 
correlated with tumor cell clumps in mouse models of fibro-
sarcoma, melanoma, and lung carcinoma (Liotta et al., 1974, 
1976; Glaves, 1983). Intravascular aggregation of cancer cells 
with apparent attachment to the endothelium has been described 
after injection of breast and prostate cancer cells as well as fibro-
sarcoma cells (Al-Mehdi et al., 2000; Glinsky et al., 2003).
The finding of CTC clusters in human blood samples might 
be limited by the technologies used for their isolation, most of 
which use harsh batch purification approaches likely to disrupt such 
cellular aggregates. Early studies in advanced prostate, breast, and 
colorectal cancers relied on gradient centrifugation in combination 
with magnetic bead selection (Brandt et al., 1996, 1998; Wang   
et al., 2000; Molnar et al., 2001). Our own recent study identified 
Figure  3.  CTC  clusters  captured  from  lung   
cancer patients’ blood using an anti-EpCAM– 
coated HB-chip. (A and B) Fluorescent micro-
graphs  of  cytokeratin  7/8  (CK;  green)–,   
CD45  (red)-,  and  DAPI  (blue)-stained  CTC 
clusters taken at different focal planes and 
corresponding hematoxylin and eosin (H&E) 
stains are shown. Bars, 10 µm.JCB • VOLUME 192 • NUMBER 3 • 2011   380
Cristofanilli, M., G.T. Budd, M.J. Ellis, A. Stopeck, J. Matera, M.C. Miller, 
J.M.  Reuben,  G.V.  Doyle,  W.J.  Allard,  L.W.  Terstappen,  and  D.F. 
Hayes.  2004.  Circulating  tumor  cells,  disease  progression,  and  sur-
vival in metastatic breast cancer. N. Engl. J. Med. 351:781–791. doi: 
10.1056/NEJMoa040766
Cristofanilli,  M.,  J.  Reuben,  and  J.  Uhr.  2008.  Circulating  tumor  cells  in 
breast  cancer:  fiction  or  reality?  J.  Clin.  Oncol.  26:3656–3657. 
doi:10.1200/JCO.2008.18.0356
Cruz, I., J. Ciudad, J.J. Cruz, M. Ramos, A. Gómez-Alonso, J.C. Adansa, C. 
Rodríguez, and A. Orfao. 2005. Evaluation of multiparameter flow cy-
tometry for the detection of breast cancer tumor cells in blood samples. 
Am. J. Clin. Pathol. 123:66–74. doi:10.1309/WP3QWKVJFYDHHXQD
Danila,  D.C.,  G.  Heller,  G.A.  Gignac,  R.  Gonzalez-Espinoza, A. Anand,  E. 
Tanaka, H. Lilja, L. Schwartz, S. Larson, M. Fleisher, and H.I. Scher. 
2007.  Circulating  tumor  cell  number  and  prognosis  in  progressive   
castration-resistant  prostate  cancer.  Clin.  Cancer  Res.  13:7053–7058. 
doi:10.1158/1078-0432.CCR-07-1506
de Bono, J.S., H.I. Scher, R.B. Montgomery, C. Parker, M.C. Miller, H. Tissing, 
G.V.  Doyle,  L.W.  Terstappen,  K.J.  Pienta,  and  D.  Raghavan.  2008. 
Circulating tumor cells predict survival benefit from treatment in meta-
static castration-resistant prostate cancer. Clin. Cancer Res. 14:6302–
6309. doi:10.1158/1078-0432.CCR-08-0872
de Cremoux, P., J.M. Extra, M.G. Denis, J.Y. Pierga, E. Bourstyn, C. Nos, K.B. 
Clough, E. Boudou, E.C. Martin, A. Müller, et al. 2000. Detection of 
MUC1-expressing  mammary  carcinoma  cells  in  the  peripheral  blood 
of breast cancer patients by real-time polymerase chain reaction. Clin. 
Cancer Res. 6:3117–3122.
Fehm, T., A. Sagalowsky, E. Clifford, P. Beitsch, H. Saboorian, D. Euhus, S. 
Meng, L. Morrison, T. Tucker, N. Lane, et al. 2002. Cytogenetic evidence 
that circulating epithelial cells in patients with carcinoma are malignant. 
Clin. Cancer Res. 8:2073–2084.
Fidler, I.J. 1973. The relationship of embolic homogeneity, number, size and 
viability  to  the  incidence  of  experimental  metastasis.  Eur.  J.  Cancer. 
9:223–227.
Galanzha, E.I., E.V. Shashkov, T. Kelly, J.W. Kim, L. Yang, and V.P. Zharov. 
2009a.  In  vivo  magnetic  enrichment  and  multiplex  photoacoustic  de-
tection of circulating tumour cells. Nat. Nanotechnol. 4:855–860. doi: 
10.1038/nnano.2009.333
Galanzha, E.I., E.V. Shashkov, P.M. Spring, J.Y. Suen, and V.P. Zharov. 2009b. 
In vivo, noninvasive, label-free detection and eradication of circulating 
metastatic melanoma cells using two-color photoacoustic flow cytometry 
with a diode laser. Cancer Res. 69:7926–7934. doi:10.1158/0008-5472 
.CAN-08-4900
Gascoyne, P.R., J. Noshari, T.J. Anderson, and F.F. Becker. 2009. Isolation of 
rare  cells  from  cell  mixtures  by  dielectrophoresis.  Electrophoresis. 
30:1388–1398. doi:10.1002/elps.200800373
Gertler, R., R. Rosenberg, K. Fuehrer, M. Dahm, H. Nekarda, and J.R. Siewert. 
2003. Detection of circulating tumor cells in blood using an optimized   
density gradient centrifugation. Recent Results Cancer Res. 162:149–155.
Ghossein, R.A., H.I. Scher, W.L. Gerald, W.K. Kelly, T. Curley, A. Amsterdam, 
Z.F. Zhang, and J. Rosai. 1995. Detection of circulating tumor cells in 
patients with localized and metastatic prostatic carcinoma: clinical impli-
cations. J. Clin. Oncol. 13:1195–1200.
Glaves, D. 1983. Correlation between circulating cancer cells and incidence of 
metastases. Br. J. Cancer. 48:665–673. doi:10.1038/bjc.1983.248
Glinsky, V.V., G.V. Glinsky, O.V. Glinskii, V.H. Huxley, J.R. Turk, V.V. Mossine, 
S.L. Deutscher, K.J. Pienta, and T.P. Quinn. 2003. Intravascular meta-
static cancer cell homotypic aggregation at the sites of primary attach-
ment to the endothelium. Cancer Res. 63:3805–3811.
Gormally, E., E. Caboux, P. Vineis, and P. Hainaut. 2007. Circulating free DNA in 
plasma or serum as biomarker of carcinogenesis: practical aspects and biologi-
cal significance. Mutat. Res. 635:105–117. doi:10.1016/j.mrrev.2006.11.002
Hardingham, J.E., P.J. Hewett, R.E. Sage, J.L. Finch, J.D. Nuttall, D. Kotasek,   
and A. Dobrovic. 2000. Molecular detection of blood-borne epithelial   
cells in colorectal cancer patients and in patients with benign bowel disease. 
Int.  J.  Cancer.  89:8–13.  doi:10.1002/(SICI)1097-0215(20000120)89: 
1<8::AID-IJC2>3.0.CO;2-K
Hayes, D.F., T.M. Walker, B. Singh, E.S. Vitetta, J.W. Uhr, S. Gross, C. Rao, G.V. 
Doyle, and L.W. Terstappen. 2002. Monitoring expression of HER-2 on 
circulating epithelial cells in patients with advanced breast cancer. Int.   
J. Oncol. 21:1111–1117.
Hayes, D.F., M. Cristofanilli, G.T. Budd, M.J. Ellis, A. Stopeck, M.C. Miller, J. 
Matera, W.J. Allard, G.V. Doyle, and L.W. Terstappen. 2006. Circulating 
tumor cells at each follow-up time point during therapy of metastatic 
breast cancer patients predict progression-free and overall survival. Clin. 
Cancer Res. 12:4218–4224. doi:10.1158/1078-0432.CCR-05-2821
He, W., H. Wang, L.C. Hartmann, J.X. Cheng, and P.S. Low. 2007. In vivo 
quantitation  of  rare  circulating  tumor  cells  by  multiphoton  intravital 
identification and analysis of metastatic precursor cell subpopu-
lations. As the technology evolves further, applications in the 
early detection of invasive but localized cancer may even be 
contemplated. Together, these advances are likely to have im-
portant implications for our understanding of cancer metastasis 
and our treatment of patients with cancer.
Submitted: 4 October 2010
Accepted: 19 January 2011
References
Aktas, B., M. Tewes, T. Fehm, S. Hauch, R. Kimmig, and S. Kasimir-Bauer. 
2009. Stem cell and epithelial-mesenchymal transition markers are fre-
quently overexpressed in circulating tumor cells of metastatic breast can-
cer patients. Breast Cancer Res. 11:R46. doi:10.1186/bcr2333
Alix-Panabières, C., J.P. Vendrell, O. Pellé, X. Rebillard, S. Riethdorf, V. Müller, 
M. Fabbro, and K. Pantel. 2007. Detection and characterization of puta-
tive metastatic precursor cells in cancer patients. Clin. Chem. 53:537–
539. doi:10.1373/clinchem.2006.079509
Alix-Panabières, C., J.P. Vendrell, M. Slijper, O. Pellé, E. Barbotte, G. Mercier, 
W. Jacot, M. Fabbro, and K. Pantel. 2009. Full-length cytokeratin-19 is 
released by human tumor cells: a potential role in metastatic progression 
of breast cancer. Breast Cancer Res. 11:R39. doi:10.1186/bcr2326
Allan, A.L., S.A. Vantyghem, A.B. Tuck, A.F. Chambers, I.H. Chin-Yee, and M. 
Keeney. 2005. Detection and quantification of circulating tumor cells in 
mouse models of human breast cancer using immunomagnetic enrich-
ment and multiparameter flow cytometry. Cytometry A. 65:4–14.
Allard, W.J., J. Matera, M.C. Miller, M. Repollet, M.C. Connelly, C. Rao, A.G. 
Tibbe, J.W. Uhr, and L.W. Terstappen. 2004. Tumor cells circulate in the 
peripheral blood of all major carcinomas but not in healthy subjects or 
patients with nonmalignant diseases. Clin. Cancer Res. 10:6897–6904. 
doi:10.1158/1078-0432.CCR-04-0378
Al-Mehdi, A.B., K. Tozawa, A.B. Fisher, L. Shientag, A. Lee, and R.J. Muschel. 
2000.  Intravascular  origin  of  metastasis  from  the  proliferation  of   
endothelium-attached tumor cells: a new model for metastasis. Nat. Med. 
6:100–102. doi:10.1038/71429
Ashworth, T.R. 1869. A case of cancer in which cells similar to those in the   
tumors were seen in the blood after death. Aust. Med. J. 14:146–149.
Attard, G., J.F. Swennenhuis, D. Olmos, A.H. Reid, E. Vickers, R. A’Hern, R. 
Levink, F. Coumans, J. Moreira, R. Riisnaes, et al. 2009. Characterization 
of ERG, AR and PTEN gene status in circulating tumor cells from pa-
tients  with  castration-resistant  prostate  cancer.  Cancer  Res.  69:2912–
2918. doi:10.1158/0008-5472.CAN-08-3667
Balasubramanian, P., L. Yang, J.C. Lang, K.R. Jatana, D. Schuller, A. Agrawal, 
M. Zborowski, and J.J. Chalmers. 2009. Confocal images of circulating 
tumor cells obtained using a methodology and technology that removes 
normal cells. Mol. Pharm. 6:1402–1408. doi:10.1021/mp9000519
Berezovskaya, O., A.D. Schimmer, A.B. Glinskii, C. Pinilla, R.M. Hoffman, J.C. 
Reed, and G.V. Glinsky. 2005. Increased expression of apoptosis inhibi-
tor protein XIAP contributes to anoikis resistance of circulating human 
prostate cancer metastasis precursor cells. Cancer Res. 65:2378–2386. 
doi:10.1158/0008-5472.CAN-04-2649
Botteri, E., M.T. Sandri, V. Bagnardi, E. Munzone, L. Zorzino, N. Rotmensz, 
C. Casadio, M.C. Cassatella, A. Esposito, G. Curigliano, et al. 2010. 
Modeling the relationship between circulating tumour cells number and 
prognosis of metastatic breast cancer. Breast Cancer Res. Treat. 122:211–
217. doi:10.1007/s10549-009-0668-7
Brandt,  B.,  R.  Junker,  C.  Griwatz,  S.  Heidl,  O.  Brinkmann, A.  Semjonow,  G. 
Assmann, and K.S. Zänker. 1996. Isolation of prostate-derived single cells 
and cell clusters from human peripheral blood. Cancer Res. 56:4556–4561.
Brandt, B., A. Roetger, S. Heidl, C. Jackisch, R.J. Lelle, G. Assmann, and K.S. 
Zänker.  1998.  Isolation  of  blood-borne  epithelium-derived  c-erbB-2 
oncoprotein-positive clustered cells from the peripheral blood of breast 
cancer  patients.  Int.  J.  Cancer.  76:824–828.  doi:10.1002/(SICI)1097-
0215(19980610)76:6<824::AID-IJC10>3.0.CO;2-2
Budd, G.T., M. Cristofanilli, M.J. Ellis, A. Stopeck, E. Borden, M.C. Miller, 
J. Matera, M. Repollet, G.V. Doyle, L.W. Terstappen, and D.F. Hayes. 
2006. Circulating tumor cells versus imaging—predicting overall sur-
vival  in  metastatic  breast  cancer.  Clin.  Cancer  Res.  12:6403–6409. 
doi:10.1158/1078-0432.CCR-05-1769
Cohen,  S.J.,  R.K.  Alpaugh,  S.  Gross,  S.M.  O’Hara,  D.A.  Smirnov,  L.W. 
Terstappen, W.J. Allard,  M.  Bilbee,  J.D.  Cheng,  J.P.  Hoffman,  et  al. 
2006. Isolation and characterization of circulating tumor cells in patients 
with metastatic colorectal cancer. Clin. Colorectal Cancer. 6:125–132. 
doi:10.3816/CCC.2006.n.029381 Visualizing and analyzing circulating tumor cells • Yu et al.
Marrinucci, D., K. Bethel, R.H. Bruce, D.N. Curry, B. Hsieh, M. Humphrey, 
R.T. Krivacic, J. Kroener, L. Kroener, A. Ladanyi, et al. 2007. Case study 
of the morphologic variation of circulating tumor cells. Hum. Pathol. 
38:514–519. doi:10.1016/j.humpath.2006.08.027
Masuda, T.A., A. Kataoka, S. Ohno, S. Murakami, K. Mimori, T. Utsunomiya, 
H. Inoue, S. Tsutsui, J. Kinoshita, N. Masuda, et al. 2005. Detection of 
occult cancer cells in peripheral blood and bone marrow by quantitative 
RT-PCR assay for cytokeratin-7 in breast cancer patients. Int. J. Oncol. 
26:721–730.
Mejean, A., G. Vona, B. Nalpas, D. Damotte, N. Brousse, Y. Chretien, B. Dufour, 
B. Lacour, C. Bréchot, and P. Paterlini-Bréchot. 2000. Detection of circu-
lating prostate derived cells in patients with prostate adenocarcinoma is 
an independent risk factor for tumor recurrence. J. Urol. 163:2022–2029. 
doi:10.1016/S0022-5347(05)67621-5
Meng, S., D. Tripathy, S. Shete, R. Ashfaq, B. Haley, S. Perkins, P. Beitsch, 
A. Khan, D. Euhus, C. Osborne, et al. 2004. HER-2 gene amplification 
can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. USA. 
101:9393–9398. doi:10.1073/pnas.0402993101
Mohamed, H., M. Murray, J.N. Turner, and M. Caggana. 2009. Isolation of   
tumor cells using size and deformation. J. Chromatogr. A. 1216:8289–
8295. doi:10.1016/j.chroma.2009.05.036
Molnar, B., A. Ladanyi, L. Tanko, L. Sréter, and Z. Tulassay. 2001. Circulating 
tumor cell clusters in the peripheral blood of colorectal cancer patients. 
Clin. Cancer Res. 7:4080–4085.
Morgan, T.M., P.H. Lange, and R.L. Vessella. 2007. Detection and characteriza-
tion of circulating and disseminated prostate cancer cells. Front. Biosci. 
12:3000–3009. doi:10.2741/2290
Müller, V., N. Stahmann, S. Riethdorf, T. Rau, T. Zabel, A. Goetz, F. Jänicke, 
and K. Pantel. 2005. Circulating tumor cells in breast cancer: correlation 
to bone marrow micrometastases, heterogeneous response to systemic 
therapy and low proliferative activity. Clin. Cancer Res. 11:3678–3685. 
doi:10.1158/1078-0432.CCR-04-2469
Nagrath, S., L.V. Sequist, S. Maheswaran, D.W. Bell, D. Irimia, L. Ulkus, M.R. 
Smith, E.L. Kwak, S. Digumarthy, A. Muzikansky, et al. 2007. Isolation 
of rare circulating tumour cells in cancer patients by microchip technol-
ogy. Nature. 450:1235–1239. doi:10.1038/nature06385
Okegawa, T., K. Nutahara, and E. Higashihara. 2009. Prognostic significance   
of circulating tumor cells in patients with hormone refractory prostate 
cancer. J. Urol. 181:1091–1097. doi:10.1016/j.juro.2008.11.015
Pachmann, K., O. Camara, A. Kavallaris, U. Schneider, S. Schünemann, and   
K. Höffken. 2005a. Quantification of the response of circulating epithelial 
cells to neodadjuvant treatment for breast cancer: a new tool for therapy 
monitoring. Breast Cancer Res. 7:R975–R979. doi:10.1186/bcr1328
Pachmann,  K.,  J.H.  Clement,  C.P.  Schneider,  B.  Willen,  O.  Camara,  U. 
Pachmann, and K. Höffken. 2005b. Standardized quantification of cir-
culating peripheral tumor cells from lung and breast cancer. Clin. Chem. 
Lab. Med. 43:617–627. doi:10.1515/CCLM.2005.107
Paez, J.G., P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. 
Kaye, N. Lindeman, T.J. Boggon, et al. 2004. EGFR mutations in lung 
cancer: correlation with clinical response to gefitinib therapy. Science. 
304:1497–1500. doi:10.1126/science.1099314
Pantel, K., R.H. Brakenhoff, and B. Brandt. 2008. Detection, clinical relevance 
and specific biological properties of disseminating tumour cells. Nat. Rev. 
Cancer. 8:329–340. doi:10.1038/nrc2375
Pao, W., V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. 
Heelan, V. Rusch, L. Fulton, et al. 2004. EGF receptor gene mutations are 
common in lung cancers from “never smokers” and are associated with 
sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA. 
101:13306–13311. doi:10.1073/pnas.0405220101
Papadopoulou, E., E. Davilas, V. Sotiriou, E. Georgakopoulos, S. Georgakopoulou, 
A. Koliopanos, F. Aggelakis, K. Dardoufas, N.J. Agnanti, I. Karydas, and 
G. Nasioulas. 2006. Cell-free DNA and RNA in plasma as a new molecu-
lar marker for prostate and breast cancer. Ann. NY Acad. Sci. 1075:235–
243. doi:10.1196/annals.1368.032
Paris, P.L., Y. Kobayashi, Q. Zhao, W. Zeng, S. Sridharan, T. Fan, H.L. Adler, 
E.R. Yera,  M.H.  Zarrabi,  S.  Zucker,  et  al.  2009.  Functional  pheno-
typing  and  genotyping  of  circulating  tumor  cells  from  patients  with 
castration resistant prostate cancer. Cancer Lett. 277:164–173. doi:10 
.1016/j.canlet.2008.12.007
Paterlini-Brechot, P., and N.L. Benali. 2007. Circulating tumor cells (CTC) de-
tection: clinical impact and future directions. Cancer Lett. 253:180–204. 
doi:10.1016/j.canlet.2006.12.014
Pierga, J.Y., F.C. Bidard, C. Mathiot, E. Brain, S. Delaloge, S. Giachetti, P. 
de  Cremoux,  R.  Salmon, A. Vincent-Salomon,  and  M.  Marty.  2008. 
Circulating tumor cell detection predicts early metastatic relapse after 
neoadjuvant chemotherapy in large operable and locally advanced breast 
cancer in a phase II randomized trial. Clin. Cancer Res. 14:7004–7010. 
doi:10.1158/1078-0432.CCR-08-0030
flow cytometry. Proc. Natl. Acad. Sci. USA. 104:11760–11765. doi:10 
.1073/pnas.0703875104
Helzer, K.T., H.E. Barnes, L. Day, J. Harvey, P.R. Billings, and A. Forsyth. 
2009.  Circulating  tumor  cells  are  transcriptionally  similar  to  the  pri-
mary tumor in a murine prostate model. Cancer Res. 69:7860–7866. 
doi:10.1158/0008-5472.CAN-09-0801
Hou, J.M., A. Greystoke, L. Lancashire, J. Cummings, T. Ward, R. Board, E. 
Amir, S. Hughes, M. Krebs, A. Hughes, et al. 2009. Evaluation of circu-
lating tumor cells and serological cell death biomarkers in small cell lung 
cancer patients undergoing chemotherapy. Am. J. Pathol. 175:808–816. 
doi:10.2353/ajpath.2009.090078
Howard, E.W., S.C. Leung, H.F. Yuen, C.W. Chua, D.T. Lee, K.W. Chan, X. 
Wang, and Y.C. Wong. 2008. Decreased adhesiveness, resistance to anoi-
kis and suppression of GRP94 are integral to the survival of circulat-
ing tumor cells in prostate cancer. Clin. Exp. Metastasis. 25:497–508. 
doi:10.1007/s10585-008-9157-3
Hüsemann, Y.,  J.B.  Geigl,  F.  Schubert,  P.  Musiani,  M.  Meyer,  E.  Burghart, 
G.  Forni,  R.  Eils,  T.  Fehm,  G.  Riethmüller,  and  C.A.  Klein.  2008. 
Systemic spread is an early step in breast cancer. Cancer Cell. 13:58–68. 
doi:10.1016/j.ccr.2007.12.003
Igetei, R., J.A. Otegbayo, D.A. Ndububa, O.A. Lesi, C.I. Anumudu, P. Hainaut, 
and E. Gormally. 2008. Detection of p53 codon 249 mutation in Nigerian 
patients with hepatocellular carcinoma using a novel evaluation of cell-
free DNA. Ann. Hepatol. 7:339–344.
Ignatiadis, M., N. Xenidis, M. Perraki, S. Apostolaki, E. Politaki, M. Kafousi, 
E.N.  Stathopoulos,  A.  Stathopoulou,  E.  Lianidou,  G.  Chlouverakis, 
et al. 2007. Different prognostic value of cytokeratin-19 mRNA posi-
tive circulating tumor cells according to estrogen receptor and HER2 
status  in  early-stage  breast  cancer.  J.  Clin.  Oncol.  25:5194–5202. 
doi:10.1200/JCO.2007.11.7762
Kallergi,  G.,  S. Agelaki, A.  Kalykaki,  C.  Stournaras,  D.  Mavroudis,  and V. 
Georgoulias. 2008. Phosphorylated EGFR and PI3K/Akt signaling ki-
nases are expressed in circulating tumor cells of breast cancer patients. 
Breast Cancer Res. 10:R80. doi:10.1186/bcr2149
Kaplan, R.N., R.D. Riba, S. Zacharoulis, A.H. Bramley, L. Vincent, C. Costa, 
D.D. MacDonald, D.K. Jin, K. Shido, S.A. Kerns, et al. 2005. VEGFR1-
positive  haematopoietic  bone  marrow  progenitors  initiate  the  pre- 
metastatic niche. Nature. 438:820–827. doi:10.1038/nature04186
Kim, M.Y., T. Oskarsson, S. Acharyya, D.X. Nguyen, X.H. Zhang, L. Norton, 
and J. Massagué. 2009. Tumor self-seeding by circulating cancer cells. 
Cell. 139:1315–1326. doi:10.1016/j.cell.2009.11.025
Krivacic, R.T., A. Ladanyi, D.N. Curry, H.B. Hsieh, P. Kuhn, D.E. Bergsrud, 
J.F. Kepros, T. Barbera, M.Y. Ho, L.B. Chen, et al. 2004. A rare-cell 
detector  for  cancer.  Proc.  Natl.  Acad.  Sci.  USA.  101:10501–10504. 
doi:10.1073/pnas.0404036101
Larson, C.J., J.G. Moreno, K.J. Pienta, S. Gross, M. Repollet, S.M. O’Hara, T. 
Russell, and L.W. Terstappen. 2004. Apoptosis of circulating tumor cells 
in prostate cancer patients. Cytometry A. 62A:46–53. doi:10.1002/cyto 
.a.20073
Leary, R.J., I. Kinde, F. Diehl, K. Schmidt, C. Clouser, C. Duncan, A. Antipova, 
C. Lee, K. McKernan, F.M. De La Vega, et al. 2010. Development of 
personalized tumor biomarkers using massively parallel sequencing. Sci 
Transl Med. 2:ra14.
Liotta, L.A., J. Kleinerman, and G.M. Saidel. 1974. Quantitative relationships 
of intravascular tumor cells, tumor vessels, and pulmonary metastases 
following tumor implantation. Cancer Res. 34:997–1004.
Liotta, L.A., M.G. Saidel, and J. Kleinerman. 1976. The significance of hematog-
enous tumor cell clumps in the metastatic process. Cancer Res. 36:889–894.
Louha, M., K. Poussin, N. Ganne, H. Zylberberg, B. Nalpas, J. Nicolet, F. Capron, 
O. Soubrane, C. Vons, S. Pol, et al. 1997. Spontaneous and iatrogenic 
spreading of liver-derived cells into peripheral blood of patients with pri-
mary liver cancer. Hepatology. 26:998–1005. doi:10.1002/hep.510260430
Lu, J., T. Fan, Q. Zhao, W. Zeng, E. Zaslavsky, J.J. Chen, M.A. Frohman, M.G. 
Golightly, S. Madajewicz, and W.T. Chen. 2010. Isolation of circulating 
epithelial and tumor progenitor cells with an invasive phenotype from breast 
cancer patients. Int. J. Cancer. 126:669–683. doi:10.1002/ijc.24814
Lynch, T.J., D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. 
Brannigan,  P.L.  Harris,  S.M.  Haserlat,  J.G.  Supko,  F.G.  Haluska,   
et al. 2004. Activating mutations in the epidermal growth factor receptor   
underlying  responsiveness  of  non-small-cell  lung  cancer  to  gefitinib.  
N. Engl. J. Med. 350:2129–2139. doi:10.1056/NEJMoa040938
Maheswaran, S., L.V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C.V. Collura, 
E. Inserra, S. Diederichs, A.J. Iafrate, D.W. Bell, et al. 2008. Detection 
of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 
359:366–377. doi:10.1056/NEJMoa0800668
Mani,  S.A.,  W.  Guo,  M.J.  Liao,  E.N.  Eaton,  A.  Ayyanan,  A.Y.  Zhou,  M.  
Brooks, F. Reinhard, C.C. Zhang, M. Shipitsin, et al. 2008. The epithelial-
mesenchymal transition  generates  cells  with  properties  of  stem  cells. 
Cell. 133:704–715. doi:10.1016/j.cell.2008.03.027JCB • VOLUME 192 • NUMBER 3 • 2011   382
the detection of rare circulating head and neck tumor cells in human pe-
ripheral blood. Cytometry B Clin. Cytom. 72:310–323.
Tsuji, T., S. Ibaragi, K. Shima, M.G. Hu, M. Katsurano, A. Sasaki, and G.F. Hu. 
2008. Epithelial-mesenchymal transition induced by growth suppressor 
p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant 
colony  growth.  Cancer  Res.  68:10377–10386.  doi:10.1158/0008-5472 
.CAN-08-1444
Tsuji,  T.,  S.  Ibaragi,  and  G.F.  Hu.  2009.  Epithelial-mesenchymal  transi-
tion  and  cell  cooperativity  in  metastasis.  Cancer  Res.  69:7135–7139. 
doi:10.1158/0008-5472.CAN-09-1618
Vona, G., A. Sabile, M. Louha, V. Sitruk, S. Romana, K. Schütze, F. Capron, 
D. Franco, M. Pazzagli, M. Vekemans, et al. 2000. Isolation by size of 
epithelial  tumor  cells  :  a  new  method  for  the  immunomorphological 
and molecular characterization of circulatingtumor cells. Am. J. Pathol. 
156:57–63.
Wang,  L.H.,  T.D.  Pfister,  R.E.  Parchment,  S.  Kummar,  L.  Rubinstein, Y.A. 
Evrard, M.E. Gutierrez, A.J. Murgo, J.E. Tomaszewski, J.H. Doroshow, 
and  R.J.  Kinders.  2010.  Monitoring  drug-induced  gammaH2AX  as  a 
pharmacodynamic biomarker in individual circulating tumor cells. Clin. 
Cancer Res. 16:1073–1084. doi:10.1158/1078-0432.CCR-09-2799
Wang, Z.P., M.A. Eisenberger, M.A. Carducci, A.W. Partin, H.I. Scher, and P.O. 
Ts’o.  2000.  Identification  and  characterization  of  circulating  prostate   
carcinoma cells. Cancer. 88:2787–2795. doi:10.1002/1097-0142(200006
15)88:12<2787::AID-CNCR18>3.0.CO;2-2
Watanabe, S. 1954. The metastasizability of tumor cells. Cancer. 7:215–223. 
doi:10.1002/1097-0142(195403)7:2<215::AID-CNCR2820070203>3.0 
.CO;2-6
Weigelt, B., A.J. Bosma, A.A. Hart, S. Rodenhuis, and L.J. van’t Veer. 2003. 
Marker genes for circulating tumour cells predict survival in metastasized 
breast cancer patients. Br. J. Cancer. 88:1091–1094. doi:10.1038/sj.bjc 
.6600868
Weight, R.M., P.S. Dale, and J.A. Viator. 2009. Detection of circulating mela-
noma cells in human blood using photoacoustic flowmetry. Conf. Proc. 
IEEE Eng. Med. Biol. Soc. 2009:106–109.
Willipinski-Stapelfeldt, B., S. Riethdorf, V. Assmann, U. Woelfle, T. Rau, G. 
Sauter, J. Heukeshoven, and K. Pantel. 2005. Changes in cytoskeletal 
protein composition indicative of an epithelial-mesenchymal transition in 
human micrometastatic and primary breast carcinoma cells. Clin. Cancer 
Res. 11:8006–8014. doi:10.1158/1078-0432.CCR-05-0632
Wu, C.H., S.R. Lin, F.J. Yu, D.C. Wu, Y.S. Pan, J.S. Hsieh, S.Y. Huang, and J.Y. 
Wang. 2006. Development of a high-throughput membrane-array method 
for molecular diagnosis of circulating tumor cells in patients with gastric 
cancers. Int. J. Cancer. 119:373–379. doi:10.1002/ijc.21856
Wülfing, P., J. Borchard, H. Buerger, S. Heidl, K.S. Zänker, L. Kiesel, and B. 
Brandt. 2006. HER2-positive circulating tumor cells indicate poor clini-
cal outcome in stage I to III breast cancer patients. Clin. Cancer Res. 
12:1715–1720. doi:10.1158/1078-0432.CCR-05-2087
Xi,  L.,  D.G.  Nicastri,  T.  El-Hefnawy,  S.J.  Hughes,  J.D.  Luketich,  and  T.E. 
Godfrey. 2007. Optimal markers for real-time quantitative reverse tran-
scription  PCR  detection  of  circulating  tumor  cells  from  melanoma, 
breast, colon, esophageal, head and neck, and lung cancers. Clin. Chem. 
53:1206–1215. doi:10.1373/clinchem.2006.081828
Yang, L., J.C. Lang, P. Balasubramanian, K.R. Jatana, D. Schuller, A. Agrawal, 
M. Zborowski, and J.J. Chalmers. 2009. Optimization of an enrichment 
process  for  circulating  tumor  cells  from  the  blood  of  head  and  neck 
cancer patients through depletion of normal cells. Biotechnol. Bioeng. 
102:521–534. doi:10.1002/bit.22066
Yoon, K.A., S. Park, S.H. Lee, J.H. Kim, and J.S. Lee. 2009. Comparison of 
circulating plasma DNA levels between lung cancer patients and healthy 
controls. J. Mol. Diagn. 11:182–185. doi:10.2353/jmoldx.2009.080098
Zanetti-Dällenbach, R., E. Wight, A.X. Fan, O. Lapaire, S. Hahn, W. Holzgreve, 
and X.Y. Zhong. 2008. Positive correlation of cell-free DNA in plasma/
serum in patients with malignant and benign breast disease. Anticancer 
Res. 28:921–925.
Zhang, Y., H. Lu, P. Dazin, and Y. Kapila. 2004. Squamous cell carcinoma cell 
aggregates escape suspension-induced, p53-mediated anoikis: fibronec-
tin and integrin alphav mediate survival signals through focal adhesion   
kinase. J. Biol. Chem. 279:48342–48349. doi:10.1074/jbc.M407953200
Zhang, Z., L. Han, L. Cao, X. Liang, Y. Liu, H. Liu, J. Du, Z. Qu, C. Zhu, S. 
Liu, et al. 2008. Aggregation formation mediated anoikis resistance of 
BEL7402  hepatoma  cells.  Folia  Histochem.  Cytobiol.  46:331–336. 
doi:10.2478/v10042-008-0042-3
Zheng, S., H. Lin, J.Q. Liu, M. Balic, R. Datar, R.J. Cote, and Y.C. Tai. 2007. 
Membrane microfilter device for selective capture, electrolysis and ge-
nomic  analysis  of  human  circulating  tumor  cells.  J.  Chromatogr.  A. 
1162:154–161. doi:10.1016/j.chroma.2007.05.064
Polyak, K., and R.A. Weinberg. 2009. Transitions between epithelial and mes-
enchymal states: acquisition of malignant and stem cell traits. Nat. Rev. 
Cancer. 9:265–273. doi:10.1038/nrc2620
Putz, E., K. Witter, S. Offner, P. Stosiek, A. Zippelius, J. Johnson, R. Zahn, G. 
Riethmüller, and K. Pantel. 1999. Phenotypic characteristics of cell lines 
derived from disseminated cancer cells in bone marrow of patients with 
solid  epithelial  tumors:  establishment  of  working  models  for  human   
micrometastases. Cancer Res. 59:241–248.
Reid, A.H., G. Attard, D.C. Danila, N.B. Oommen, D. Olmos, P.C. Fong, L.R. 
Molife, J. Hunt, C. Messiou, C. Parker, et al. 2010. Significant and sus-
tained antitumor activity in post-docetaxel, castration-resistant prostate 
cancer  with  the  CYP17  inhibitor  abiraterone  acetate.  J.  Clin.  Oncol. 
28:1489–1495. doi:10.1200/JCO.2009.24.6819
Riethdorf,  S.,  H.  Fritsche, V.  Müller,  T.  Rau,  C.  Schindlbeck,  B.  Rack, W. 
Janni, C. Coith, K. Beck, F. Jänicke, et al. 2007. Detection of circulating   
tumor cells in peripheral blood of patients with metastatic breast cancer:   
a validation study of the CellSearch system. Clin. Cancer Res. 13:920–
928. doi:10.1158/1078-0432.CCR-06-1695
Schardt,  J.A.,  M.  Meyer,  C.H.  Hartmann,  F.  Schubert,  O.  Schmidt-Kittler, 
C. Fuhrmann, B. Polzer, M. Petronio, R. Eils, and C.A. Klein. 2005. 
Genomic analysis of single cytokeratin-positive cells from bone marrow 
reveals early mutational events in breast cancer. Cancer Cell. 8:227–239. 
doi:10.1016/j.ccr.2005.08.003
Scher, H.I., X. Jia, J.S. de Bono, M. Fleisher, K.J. Pienta, D. Raghavan, and G. 
Heller. 2009. Circulating tumour cells as prognostic markers in progres-
sive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial 
data. Lancet Oncol. 10:233–239. doi:10.1016/S1470-2045(08)70340-1
Schmidt, H., G. DeAngelis, E. Eltze, I. Gockel, A. Semjonow, and B. Brandt. 
2006. Asynchronous  growth  of  prostate  cancer  is  reflected  by  circu-
lating  tumor  cells  delivered  from  distinct,  even  small  foci,  harboring 
loss of heterozygosity of the PTEN gene. Cancer Res. 66:8959–8965. 
doi:10.1158/0008-5472.CAN-06-1722
Schwarzenbach,  H.,  F.K.  Chun,  I.  Lange,  S.  Carpenter,  M.  Gottberg,  A. 
Erbersdobler, M.G. Friedrich, H. Huland, and K. Pantel. 2007. Detection of 
tumor-specific DNA in blood and bone marrow plasma from patients with 
prostate cancer. Int. J. Cancer. 120:1465–1471. doi:10.1002/ijc.22470
Schwarzenbach, H., C. Alix-Panabières, I. Müller, N. Letang, J.P. Vendrell, X. 
Rebillard, and K. Pantel. 2009. Cell-free tumor DNA in blood plasma as 
a marker for circulating tumor cells in prostate cancer. Clin. Cancer Res. 
15:1032–1038. doi:10.1158/1078-0432.CCR-08-1910
Sieuwerts, A.M., J. Kraan, J. Bolt, P. van der Spoel, F. Elstrodt, M. Schutte, 
J.W. Martens, J.W. Gratama, S. Sleijfer, and J.A. Foekens. 2009. Anti- 
epithelial cell adhesion molecule antibodies and the detection of circulat-
ing normal-like breast tumor cells. J. Natl. Cancer Inst. 101:61–66.
Simpson, S.J., M. Vachula, M.J. Kennedy, H. Kaizer, J.S. Coon, R. Ghalie, S. 
Williams, and D. Van Epps. 1995. Detection of tumor cells in the bone 
marrow, peripheral blood, and apheresis products of breast cancer pa-
tients using flow cytometry. Exp. Hematol. 23:1062–1068.
Stott, S.L., R.J. Lee, S. Nagrath, M. Yu, D.T. Miyamoto, L. Ulkus, E.J. Inserra, 
M. Ulman, S. Springer, Z. Nakamura, et al. 2010a. Isolation and charac-
terization of circulating tumor cells from localized and metastatic pros-
tate cancer patients. Sci. Transl. Med. 2:25ra23.
Stott, S.L., C.H. Hsu, D.I. Tsukrov, M. Yu, D.T. Miyamoto, B.A. Waltman, S.M. 
Rothenberg, A.M. Shah, M.E. Smas, G.K. Korir, et al. 2010b. Isolation of cir-
culating tumor cells using a microvortex-generating herringbone-chip. Proc. 
Natl. Acad. Sci. USA. 107:18392–18397. doi:10.1073/pnas.1012539107
Swennenhuis, J.F., A.G. Tibbe, R. Levink, R.C. Sipkema, and L.W. Terstappen. 
2009. Characterization of circulating tumor cells by fluorescence in situ 
hybridization. Cytometry A. 75:520–527.
Talasaz, A.H., A.A. Powell, D.E. Huber, J.G. Berbee, K.H. Roh, W. Yu, W. Xiao, 
M.M. Davis, R.F. Pease, M.N. Mindrinos, et al. 2009. Isolating highly 
enriched populations of circulating epithelial cells and other rare cells 
from blood using a magnetic sweeper device. Proc. Natl. Acad. Sci. USA. 
106:3970–3975. doi:10.1073/pnas.0813188106
Tan, S.J., L. Yobas, G.Y. Lee, C.N. Ong, and C.T. Lim. 2009. Microdevice 
for the isolation and enumeration of cancer cells from blood. Biomed. 
Microdevices. 11:883–892. doi:10.1007/s10544-009-9305-9
Tewes, M., B. Aktas, A. Welt, S. Mueller, S. Hauch, R. Kimmig, and S. Kasimir-
Bauer. 2009. Molecular profiling and predictive value of circulating tumor 
cells in patients with metastatic breast cancer: an option for monitoring 
response to breast cancer related therapies. Breast Cancer Res. Treat. 
115:581–590. doi:10.1007/s10549-008-0143-x
Tkaczuk, K.H., O. Goloubeva, N.S. Tait, F. Feldman, M. Tan, Z.P. Lum, S.A. 
Lesko, D.A. Van Echo, and P.O. Ts’o. 2008. The significance of cir-
culating  epithelial  cells  in  Breast  Cancer  patients  by  a  novel  nega-
tive  selection  method.  Breast  Cancer  Res.  Treat.  111:355–364.  doi: 
10.1007/s10549-007-9771-9
Tong, X., L. Yang, J.C. Lang, M. Zborowski, and J.J. Chalmers. 2007. Application   
of immunomagnetic cell enrichment in combination with RT-PCR for 